Invitrocue Ltd. provides bio analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. The company focuses on the commercialization of its bio analytics services using cell based model and imaging based technology. Its cell based services enable pharmaceutical and cosmetics companies to refine their drug, ingredient, compound or vaccine discovery efforts and digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online web-based portal. Invitrocue founded on January 31, 1989 and is headquartered in Sydney, Australia.
|Market Price at 17-11-2017||$0.09|
|Price to Earnings Ratio||-15.23|
|Market Capitalisation||$40.74 (million)|
|Return on Equity (ROE)||-2,187.5%|